ATXS
Astria Therapeutics Inc.
Company Overview
| Mkt Cap | $702.05M | Price | $12.51 |
| Volume | 653.01K | Change | +0.48% |
| P/E Ratio | -7.4 | Open | $12.43 |
| Revenue | -- | Prev Close | $12.45 |
| Net Income | $-94.3M | 52W Range | $3.56 - $12.72 |
| Div Yield | N/A | Target | $20.00 |
| Overall | 63 | Value | 60 |
| Quality | -- | Technical | 66 |
No chart data available
About Astria Therapeutics Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Latest News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS), Milestone Pharmaceuticals (MIST) and Astria Therapeutics (ATXS)
Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATXS | $12.51 | +0.5% | 653.01K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Astria Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW